Table 2.
Association between high-flow nasal cannula oxygenation (HFNCO) and in-hospital outcome in SARS-CoV-2-related acute respiratory failure, before and after adjustment for confounders by stabilized inverse probability weighting.
| Crude Hazard Ratio | Weighted Hazard Ratio | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | p | HR (95% CI) | p |
| Survival at 30 days | 0.58 (0.34–0.99) | 0.04 | 0.57 (0.33–0.99) | 0.04 |
| Morphine introduction | 0.40 (0.23–0.70) | 0.002 | 0.39 (0.21–0.71) | 0.002 |
| Midazolam introduction | 0.71 (0.40–1.28) | 0.26 | 0.66 (0.37–1.19) | 0.17 |